Sanuwave lowers Q2 2026 guidance to $8.5-$9.5M due to market disruption
Sanuwave Health reduced its Q2 2026 revenue guidance below prior expectations due to CMS reimbursement clawbacks forcing wound care practices to close and flood the market with used Ultramist systems. While consumable applicator volumes remain robust, capital equipment sales face near-term headwinds from used system cannibalization.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day